First Citizens Bank & Trust Co. Sells 3,169 Shares of Johnson & Johnson (NYSE:JNJ)

First Citizens Bank & Trust Co. trimmed its position in shares of Johnson & Johnson (NYSE:JNJ) by 4.3% in the 4th quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 70,744 shares of the company’s stock after selling 3,169 shares during the quarter. First Citizens Bank & Trust Co.’s holdings in Johnson & Johnson were worth $10,231,000 as of its most recent filing with the Securities & Exchange Commission.

A number of other hedge funds have also recently modified their holdings of the business. IFS Advisors LLC lifted its stake in shares of Johnson & Johnson by 138.9% during the 4th quarter. IFS Advisors LLC now owns 172 shares of the company’s stock worth $25,000 after purchasing an additional 100 shares during the last quarter. Highline Wealth Partners LLC purchased a new position in Johnson & Johnson during the 3rd quarter worth $31,000. RPg Family Wealth Advisory LLC acquired a new position in shares of Johnson & Johnson during the third quarter valued at about $35,000. Mowery & Schoenfeld Wealth Management LLC raised its holdings in shares of Johnson & Johnson by 58.7% in the third quarter. Mowery & Schoenfeld Wealth Management LLC now owns 246 shares of the company’s stock worth $40,000 after buying an additional 91 shares during the last quarter. Finally, Activest Wealth Management acquired a new stake in Johnson & Johnson during the 3rd quarter worth about $40,000. Institutional investors own 69.55% of the company’s stock.

Analyst Ratings Changes

JNJ has been the topic of several recent research reports. Royal Bank of Canada reaffirmed an “outperform” rating and issued a $181.00 price target on shares of Johnson & Johnson in a report on Thursday, January 23rd. Wolfe Research assumed coverage on shares of Johnson & Johnson in a research note on Friday, November 15th. They set an “outperform” rating and a $190.00 target price on the stock. Wells Fargo & Company reduced their price objective on Johnson & Johnson from $166.00 to $152.00 and set an “equal weight” rating on the stock in a research report on Thursday, January 23rd. Leerink Partners cut their target price on Johnson & Johnson from $182.00 to $169.00 and set an “outperform” rating on the stock in a research report on Thursday, January 23rd. Finally, Morgan Stanley lowered their target price on Johnson & Johnson from $175.00 to $163.00 and set an “equal weight” rating for the company in a research note on Thursday, January 23rd. Nine research analysts have rated the stock with a hold rating, eight have given a buy rating and two have given a strong buy rating to the stock. According to MarketBeat.com, Johnson & Johnson has a consensus rating of “Moderate Buy” and an average price target of $170.44.

Johnson & Johnson Price Performance

Johnson & Johnson stock opened at $150.63 on Wednesday. The firm has a fifty day moving average of $147.81 and a 200-day moving average of $156.12. The firm has a market capitalization of $362.65 billion, a P/E ratio of 22.65, a PEG ratio of 2.45 and a beta of 0.51. Johnson & Johnson has a 52-week low of $140.68 and a 52-week high of $168.85. The company has a quick ratio of 0.79, a current ratio of 1.03 and a debt-to-equity ratio of 0.45.

Johnson & Johnson (NYSE:JNJ) last released its earnings results on Wednesday, January 22nd. The company reported $2.04 EPS for the quarter, topping analysts’ consensus estimates of $1.99 by $0.05. The company had revenue of $22.52 billion for the quarter, compared to the consensus estimate of $22.44 billion. Johnson & Johnson had a return on equity of 34.35% and a net margin of 18.20%. Johnson & Johnson’s quarterly revenue was up 5.3% compared to the same quarter last year. During the same quarter last year, the business posted $2.29 EPS. As a group, analysts predict that Johnson & Johnson will post 10.56 EPS for the current year.

Johnson & Johnson Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 4th. Investors of record on Tuesday, February 18th will be paid a dividend of $1.24 per share. The ex-dividend date of this dividend is Tuesday, February 18th. This represents a $4.96 annualized dividend and a yield of 3.29%. Johnson & Johnson’s dividend payout ratio (DPR) is 74.59%.

Insider Activity

In other Johnson & Johnson news, Director Mark A. Weinberger acquired 1,000 shares of Johnson & Johnson stock in a transaction dated Thursday, December 12th. The stock was acquired at an average cost of $147.22 per share, for a total transaction of $147,220.00. Following the completion of the transaction, the director now owns 1,000 shares in the company, valued at approximately $147,220. This represents a ∞ increase in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. Corporate insiders own 0.16% of the company’s stock.

About Johnson & Johnson

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension.